Biotech Strategy Blog

Commentary on Science, Innovation & New Products

Posts tagged ‘New Prostate Cancer Drugs’

AACR 2012: AZD3514 a new prostate cancer drug to watch

By on April 17, 2012

AACR 2012 Chicago Airport Sign 300x225 AACR 2012: AZD3514 a new prostate cancer drug to watchAs Sally Church, PhD noted on Pharma Strategy Blog, the 2012 annual meeting of the American Association for Cancer Research (AACR), recently held in Chicago, showcased many new cancer products in early development.

Cancer new products have a high attrition rate as they move through the development pipeline, so any promising results seen in early stages of development must be viewed with caution.

Results from laboratory studies using cell lines or trials in animals do not always translate into new drugs that work in man, e.g. they may have an unacceptable toxicity, not target the driver mutation, or adaptive resistance may just lead to the cancer bypassing the blocked pathway.

This is a preview of AACR 2012: AZD3514 a new prostate cancer drug to watch. Read the full post

1 Comment

Cabozantinib & Pain in Prostate Cancer – an interview with Dr Maha Hussain

By on March 12, 2012

Maha Hussain MB ChB is Professor of Medical Oncology at the University of Michigan.  She is an international expert into genitourinary malignancies with a focus on clinical research into prostate and bladder cancer.

ASCO 2011 Cabozantinib Presentation Title Slide 300x225 Cabozantinib & Pain in Prostate Cancer an interview with Dr Maha Hussain

Cabozantinib is a new drug in development by Exelixis for multiple indications.  It captured a lot of attention at the ASCO 2011 annual meeting last year, when Dr Hussain presented data from a phase 2 prostate cancer trial that showed a dramatic improvement in bone scans and pain reduction in those men receiving it.

This is a preview of Cabozantinib & Pain in Prostate Cancer – an interview with Dr Maha Hussain. Read the full post

1 Comment

European Association of Urology 2012 #EAU12 Twitter Coverage

By on February 24, 2012

View of Paris from EAU 2012 Congress 300x168 European Association of Urology 2012 #EAU12 Twitter CoverageToday sees the start of the 27th annual European Association of Urology (EAU) Congress at the Palais des Congrès in Paris.

The meeting runs from 24-28 February, 2012. Over 10,000 delegates are expected, and more than 1193 abstracts have been accepted for poster and video sessions.

In addition to a scientific programme, this meeting also has a strong educational component with numerous courses through the European School of Urology (ESU) and hands-on-training to improve surgical skills in cooperation with the EAU Section of Uro-Technology (ESUT), the EAU Section of Urolithiasis (EULIS) and the EAU Section of Robotic Urology (ERUS).

This is a preview of European Association of Urology 2012 #EAU12 Twitter Coverage. Read the full post

Leave a comment

Scientific Symposia at ECCO ESMO 2011 Stockholm Cancer Congress

By on September 17, 2011

Screen shot 2011 09 17 at 1.32.05 PM Scientific Symposia at ECCO ESMO 2011 Stockholm Cancer Congress I will be flying to Stockholm next week for the European Multidisciplinary Cancer Congress (twitter #EMCC2011), more commonly known as ECCO or ESMO 2011.

What are the sessions that look interesting at the meeting? I previously wrote about the phase III ALSYMPCA trial data for Alpharadin that will be presented as a late breaking abstract.

In addition, the best abstract at ECCO 2011 is on vismodegib in basal cell carcinoma.  Sally Church on Pharma Strategy Blog has written extensively about the hedgehog pathway and role of smoothend inhibition in the treatment of cancer.

This is a preview of Scientific Symposia at ECCO ESMO 2011 Stockholm Cancer Congress. Read the full post

Leave a comment